22–23 Jul 2026
Heidelberg Congress Center
Europe/Berlin timezone

Functional Reserve and Sarcopenia Shape Treatment Outcomes After CAR-T Cell Treatment: Results of a Real-World Pilot Study

22 Jul 2026, 15:45
15m
Heidelberg Congress Center ( Heidelberg Congress Center )

Heidelberg Congress Center

Heidelberg Congress Center

Czernyring 20 69115 Heidelberg Germany
3 - Talk Oral Session

Speaker

Alessandra Holzem (Department of Medicine III, LMU Hospital Munich)

Description

Objective
Assessment of patient fitness before CAR-T cell therapy relies on the subjective ECOG performance status (PS), offering limited granularity for clinical decision-making. To establish a more objective reproducible evaluation, we implemented two standardized bedside physical performance tests. In this prospective pilot study, we investigated whether quantitative measures of functional capacity provide discriminatory value for improved risk stratification of CAR-T outcomes.
Methods
90 patients were screened and 66 enrolled for standard-of-care CD19- or BCMA-directed CAR-T cell therapy for LBCL, MCL, B-ALL, or MM between 04/2024–11/2025. In addition to ECOG PS, patients completed a 10-meter walk test and a 30-second sit-to-stand test. Individuals meeting reference values for both tests were classified as fit; failure of one or both tests defined the unfit group. Clinical endpoints included CRS, ICANS, ICAHT, overall survival (OS), progression-free survival (PFS), and non-relapse mortality (NRM). Body composition was quantified on pre-treatment PET/CT scans using an AI-based segmentation tool (Ship-AI), capturing adipose tissue compartments (TAT, VAT, IMAT) and skeletal muscle measures (SMI, SI). Kaplan–Meier analyses assessed survival outcomes.
Results
The cohort comprised 32 fit (48%) and 34 unfit (52%) patients (median age 63, ECOG 0: 23% ECOG 1: 70%, ECOG ≥2: 6%). ECOG PS was similarly distributed between groups (p=0.55) and did not discriminate survival outcomes, whereas the fitness assessment demonstrated a trend toward improved OS (p=0.068). When integrated with sarcopenia metrics, the model provided significantly greater survival discrimination (p=0.037). CRS and ICANS rates did not differ between groups. Fit patients showed higher SMI and SI, indicating better muscle reserves. Gait speed correlated inversely with adipose tissue (IMAT p=0.003; TAT p=0.041; VAT p=0.048).
Conclusions
This study demonstrated feasibility and clinical relevance of standardized fitness metrics before CAR-T therapy. The combination of impaired physical performance and low muscle mass identifies a high-risk phenotype associated with inferior survival.

Keywords

Functional fitness, sarcopenia, real-world, risk stratification

Abstract submitters declaration yes
Conflict of Interest & Ethical Approval yes

Author

Alessandra Holzem (Department of Medicine III, LMU Hospital Munich)

Co-authors

Anna Magee (Physical Therapy Unit, LMU Hospital Munich) Veronika Kezzo (Physical Therapy Unit, LMU Hospital Munich) Marvin Sprengart (Physical Therapy Unit, LMU Hospital Munich) Tsitou Panagiota-Eirini (Physical Therapy Unit, LMU Hospital Munich) David Götzinger (Department of Radiology, LMU Hospital Munich) Dr Tobias Tix (Department of Medicine III, LMU Hospital Munich) Dr Sophia Stock (Department of Medicine III, LMU Hospital Munich) Dr Giulia Magno (Department of Medicine III, LMU Hospital Munich) Dr Adrian Gottschlich (Department of Medicine III, LMU Hospital Munich) Linus Kruk (Department of Medicine III, LMU Hospital Munich) Wajma Shahbaz (Department of Medicine III, LMU Hospital Munich) Michaela Braxenthaler (Physical Therapy Unit, LMU Hospital Munich) Prof. Michael von Bergwelt-Baildon (Department of Medicine III, LMU Hospital Munich) Prof. Wolfgang Kunz (Department of Radiology, LMU Hospital Munich) Dr Veit Bücklein (Department of Medicine III, LMU Hospital Munich) Prof. Sebastian Theurich (Department of Medicine III, LMU Hospital Munich) Prof. Michael Ingrisch (Department of Radiology, LMU Hospital Munich) Prof. Marion Subklewe (Department of Medicine III, LMU Hospital Munich) Dr Kai Rejeski (Department of Medicine III, LMU Hospital Munich)

Presentation materials

There are no materials yet.